Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
Becker's Hospital Review7h
'It's a fine balance': CFOs struggle to manage GLP-1 access and costs
Learn about the financial strain caused by the skyrocketing demand and costs of GLP-1 drugs, and how health plans and providers are struggling to balance it.
Cosmos Health advances weight management device to clinical trials
CHICAGO - Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group with a market capitalization of $15.11 million, is ...
pharmaphorum10h
Looking beyond the scale: Why measures of physical activity should be incorporated into obesity trials to support long-term sustainable weight loss
This can help individuals feel fuller for longer and can promote weight loss. When measured by traditional weight loss ...
Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugs
The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.